Targeting smokers at increased risk for relapse: Treating women and those with a history of depression

Stevens S. Smith, Douglas E. Jorenby, Scott J. Leischow, Mitchell A. Nides, Stephen I. Rennard, J. Andrew Johnston, Brenda Jamerson, Michael C. Fiore, Timothy B. Baker

Research output: Contribution to journalReview articlepeer-review

72 Scopus citations


Some studies have shown that female smokers and smokers with a history of depression have an increased risk of relapse following smoking cessation treatment. This study examined the efficacy of bupropion sustained-release (SR) and the nicotine patch for smoking cessation in subgroups of smokers at possible risk for relapse. Data for this study were from a previously published randomized, double-blind, placebo-controlled clinical trial in which 893 smokers were randomized to four treatment conditions: placebo tablet+placebo patch, placebo tablet+21 mg/24-hr nicotine patch, 300 mg bupropion SR+placebo patch, and 300 mg bupropion SR+21 mg/24-hr nicotine patch. Study medication continued for 8 weeks after the quit day; brief individual cessation counseling was provided during weekly clinic visits. In comparison to the placebo tablet, bupropion SR approximately tripled 1-year non-smoking rates among women and previously depressed individuals. In contrast, the nicotine patch did not significantly improve cessation rates for any group. We conclude that bupropion SR is a first-line treatment for smoking that has the potential to benefit all smokers, especially women and the previously depressed.

Original languageEnglish (US)
Pages (from-to)99-109
Number of pages11
JournalNicotine and Tobacco Research
Issue number1
StatePublished - Feb 2003
Externally publishedYes

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Targeting smokers at increased risk for relapse: Treating women and those with a history of depression'. Together they form a unique fingerprint.

Cite this